Inhaled Insulin: A Proof-of-Concept Study

  1. William T. Cefalu, MD
  1. University of Vermont College of Medicine; Burlington, VT 05401 (Cefalu)

    The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:

    •Include no more than 300 words of text, three authors, and five references

    •Type with double-spacing

    •Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.

    Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.

    Annals welcomes electronically submitted letters.

    TO THE EDITOR:

    The editorial (1) about our article on insulin therapy (2) requires some clarification because information that answers many of the issues raised was not available to the editorialist.

    Ours was a proof-of-concept study. Half of the participants in this open-label, …

    « Previous | Next Article »Table of Contents